Background: Microarray gene expression technology has become standard practice in systems biology to analyze transcriptomic changes at the cell, tissue, and organism level, enabling the reverse-engineering of condition-specific gene networks. Purpose: To better understand how transcriptional gene networks of biologically close cellular systems, differ, two specific networks were reverse-engineered from 2D and 3D human normal bronchial epithelial cell cultures. Methods: 100 gene expression profiles for both normal human bronchial epithelial (NHBE) cells and organotypically differentiated bronchial cells (AIR100 culture) were collected under normal culture conditions. Gene networks were reconstructed by correlating gene expression profiles at a false discovery rate (FDR, T-statistic and Benjamini-Hochberg correction).
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.